Lau, David C. W.
Shaw, Eileen
McMullen, Suzanne
Cowling, Tara
Witges, Kelcie
Amitay, Efrat L.
Steubl, Dominik
Girard, Louis P.
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 5 June 2023
Accepted: 20 July 2024
First Online: 29 July 2024
Declarations
:
: Research ethics board approval was obtained from the Health Research Ethics Board of Alberta – Community Health Committee (HREBA-CHC) with a waiver of consent (HREBA.CHC-20-0017). All the methods included in this study are in accordance with the declaration of Helsinki.
: N/A.
: DCWL reports receiving grants and research support from Amgen, Boehringer-Ingelheim, Novo Nordisk and the Canadian Institutes of Health Research (CIHR); speaker bureau fees from Bayer, Boehringer Ingelheim, Can. Collaborative Research Network, CME at Sea, Eli Lilly, Novartis and Novo Nordisk; and consulting fees from Alnylam, Amgen, Bayer, Boehringer Ingelheim, HLS Therapeutics, Eli Lilly and Novo Nordisk and Viatris. ES, SM, TC, and KW are employed by Medlior, which received funding for the study from Boehringer Ingelheim. ELA and DS are employed by Boehringer Ingelheim who funded this study. LPG reports receiving honoraria for his involvement in continuing medical education and his participation in advisory boards from AstraZeneca, Boehringer Ingelheim, CPD Network, Eli Lilly, Janssen, Merck, and Otsuka Canada.